Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Assessing the usefulness of transition metal carbides for hydrogenation reactions.

Prats H, Piñero JJ, Viñes F, Bromley ST, Sayós R, Illas F.

Chem Commun (Camb). 2019 Nov 4;55(85):12797-12800. doi: 10.1039/c9cc06084g. Epub 2019 Oct 8.

PMID:
31593204
2.

Room Temperature Methane Capture and Activation by Ni Clusters Supported on TiC(001): Effects of Metal-Carbide Interactions on the Cleavage of the C-H Bond.

Prats H, Gutiérrez RA, Piñero JJ, Viñes F, Bromley ST, Ramírez PJ, Rodriguez JA, Illas F.

J Am Chem Soc. 2019 Apr 3;141(13):5303-5313. doi: 10.1021/jacs.8b13552. Epub 2019 Mar 18.

PMID:
30848129
3.

Api5 a new cofactor of estrogen receptor alpha involved in breast cancer outcome.

Basset C, Bonnet-Magnaval F, Navarro MG, Touriol C, Courtade M, Prats H, Garmy-Susini B, Lacazette E.

Oncotarget. 2017 Apr 20;8(32):52511-52526. doi: 10.18632/oncotarget.17281. eCollection 2017 Aug 8.

4.

Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin.

Le Gonidec S, Chaves-Almagro C, Bai Y, Kang HJ, Smith A, Wanecq E, Huang XP, Prats H, Knibiehler B, Roth BL, Barak LS, Caron MG, Valet P, Audigier Y, Masri B.

FASEB J. 2017 Jun;31(6):2507-2519. doi: 10.1096/fj.201601074R. Epub 2017 Feb 27.

5.

Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.

Quemener C, Baud J, Boyé K, Dubrac A, Billottet C, Soulet F, Darlot F, Dumartin L, Sire M, Grepin R, Daubon T, Rayne F, Wodrich H, Couvelard A, Pineau R, Schilling M, Castronovo V, Sue SC, Clarke K, Lomri A, Khatib AM, Hagedorn M, Prats H, Bikfalvi A.

Cancer Res. 2016 Nov 15;76(22):6507-6519. doi: 10.1158/0008-5472.CAN-15-2864. Epub 2016 Sep 9.

6.

Hypoxia and ER stress promote Staufen1 expression through an alternative translation mechanism.

Bonnet-Magnaval F, Philippe C, Van Den Berghe L, Prats H, Touriol C, Lacazette E.

Biochem Biophys Res Commun. 2016 Oct 14;479(2):365-371. doi: 10.1016/j.bbrc.2016.09.082. Epub 2016 Sep 17.

PMID:
27644878
7.

PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress.

Philippe C, Dubrac A, Quelen C, Desquesnes A, Van Den Berghe L, Ségura C, Filleron T, Pyronnet S, Prats H, Brousset P, Touriol C.

Sci Signal. 2016 May 3;9(426):ra44. doi: 10.1126/scisignal.aaf2753.

PMID:
27141928
8.

A novel cytoprotective function for the DNA repair protein Ku in regulating p53 mRNA translation and function.

Lamaa A, Le Bras M, Skuli N, Britton S, Frit P, Calsou P, Prats H, Cammas A, Millevoi S.

EMBO Rep. 2016 Apr;17(4):508-18. doi: 10.15252/embr.201541181. Epub 2016 Mar 10.

9.

Unexpectedly large impact of van der Waals interactions on the description of heterogeneously catalyzed reactions: the water gas shift reaction on Cu(321) as a case example.

Prats H, Gamallo P, Sayós R, Illas F.

Phys Chem Chem Phys. 2016 Jan 28;18(4):2792-801. doi: 10.1039/c5cp06863k.

PMID:
26727174
10.

Key contribution of eIF4H-mediated translational control in tumor promotion.

Vaysse C, Philippe C, Martineau Y, Quelen C, Hieblot C, Renaud C, Nicaise Y, Desquesnes A, Pannese M, Filleron T, Escourrou G, Lawson M, Rintoul RC, Delisle MB, Pyronnet S, Brousset P, Prats H, Touriol C.

Oncotarget. 2015 Nov 24;6(37):39924-40. doi: 10.18632/oncotarget.5442.

11.

Glioblastoma invasion and cooption depend on IRE1α endoribonuclease activity.

Jabouille A, Delugin M, Pineau R, Dubrac A, Soulet F, Lhomond S, Pallares-Lupon N, Prats H, Bikfalvi A, Chevet E, Touriol C, Moenner M.

Oncotarget. 2015 Sep 22;6(28):24922-34. doi: 10.18632/oncotarget.4679.

12.

Stabilization of the G-quadruplex at the VEGF IRES represses cap-independent translation.

Cammas A, Dubrac A, Morel B, Lamaa A, Touriol C, Teulade-Fichou MP, Prats H, Millevoi S.

RNA Biol. 2015;12(3):320-9. doi: 10.1080/15476286.2015.1017236.

13.

CXCR4 is highly expressed at the tumor front but not in the center of prostate cancers.

Delongchamps NB, Beuvon F, Mathieu JR, Delmas S, Metzger I, Prats H, Cabon F.

World J Urol. 2015 Feb;33(2):281-7. doi: 10.1007/s00345-014-1299-0. Epub 2014 Apr 19.

PMID:
24748552
14.

ReaxFF molecular dynamics simulations of CO collisions on an O-preadsorbed silica surface.

Gamallo P, Prats H, Sayós R.

J Mol Model. 2014 Apr;20(4):2160. doi: 10.1007/s00894-014-2160-5. Epub 2014 Mar 16.

PMID:
24633769
15.

Tumour co-expression of apelin and its receptor is the basis of an autocrine loop involved in the growth of colon adenocarcinomas.

Picault FX, Chaves-Almagro C, Projetti F, Prats H, Masri B, Audigier Y.

Eur J Cancer. 2014 Feb;50(3):663-74. doi: 10.1016/j.ejca.2013.11.017. Epub 2013 Dec 5.

PMID:
24316062
16.

E2F1 activates p53 transcription through its distal site and participates in apoptosis induction in HPV-positive cells.

Massip A, Arcondéguy T, Touriol C, Basset C, Prats H, Lacazette E.

FEBS Lett. 2013 Oct 1;587(19):3188-94. doi: 10.1016/j.febslet.2013.08.009. Epub 2013 Aug 13.

17.

Api5 contributes to E2F1 control of the G1/S cell cycle phase transition.

Garcia-Jove Navarro M, Basset C, Arcondéguy T, Touriol C, Perez G, Prats H, Lacazette E.

PLoS One. 2013 Aug 7;8(8):e71443. doi: 10.1371/journal.pone.0071443. Print 2013.

18.

VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level.

Arcondéguy T, Lacazette E, Millevoi S, Prats H, Touriol C.

Nucleic Acids Res. 2013 Sep;41(17):7997-8010. doi: 10.1093/nar/gkt539. Epub 2013 Jul 12. Review.

19.

CXCL4L1-fibstatin cooperation inhibits tumor angiogenesis, lymphangiogenesis and metastasis.

Prats AC, Van den Berghe L, Rayssac A, Ainaoui N, Morfoisse F, Pujol F, Legonidec S, Bikfalvi A, Prats H, Pyronnet S, Garmy-Susini B.

Microvasc Res. 2013 Sep;89:25-33. doi: 10.1016/j.mvr.2013.05.005. Epub 2013 Jun 4.

20.

Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1.

Kuo JH, Chen YP, Liu JS, Dubrac A, Quemener C, Prats H, Bikfalvi A, Wu WG, Sue SC.

J Biol Chem. 2013 May 10;288(19):13522-33. doi: 10.1074/jbc.M113.455329. Epub 2013 Mar 27.

21.

Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.

Dejean E, Renalier MH, Foisseau M, Agirre X, Joseph N, de Paiva GR, Al Saati T, Soulier J, Desjobert C, Lamant L, Prósper F, Felsher DW, Cavaillé J, Prats H, Delsol G, Giuriato S, Meggetto F.

Leukemia. 2011 Dec;25(12):1882-90. doi: 10.1038/leu.2011.168. Epub 2011 Jul 22.

PMID:
21778999
22.

Functional divergence between 2 chemokines is conferred by single amino acid change.

Dubrac A, Quemener C, Lacazette E, Lopez F, Zanibellato C, Wu WG, Bikfalvi A, Prats H.

Blood. 2010 Nov 25;116(22):4703-11. doi: 10.1182/blood-2010-03-274852. Epub 2010 Aug 5.

PMID:
20688960
23.

Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism.

Haurie V, Ménard L, Nicou A, Touriol C, Metzler P, Fernandez J, Taras D, Lestienne P, Balabaud C, Bioulac-Sage P, Prats H, Zucman-Rossi J, Rosenbaum J.

Hepatology. 2009 Dec;50(6):1871-83. doi: 10.1002/hep.23215.

24.

Pivotal role of translokin/CEP57 in the unconventional secretion versus nuclear translocation of FGF2.

Meunier S, Navarro MG, Bossard C, Laurell H, Touriol C, Lacazette E, Prats H.

Traffic. 2009 Dec;10(12):1765-72. doi: 10.1111/j.1600-0854.2009.00985.x. Epub 2009 Sep 14.

25.

Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production.

Fallot S, Ben Naya R, Hieblot C, Mondon P, Lacazette E, Bouayadi K, Kharrat A, Touriol C, Prats H.

Nucleic Acids Res. 2009 Nov;37(20):e134. doi: 10.1093/nar/gkp716. Epub 2009 Sep 3.

26.

The StkP/PhpP signaling couple in Streptococcus pneumoniae: cellular organization and physiological characterization.

Osaki M, Arcondéguy T, Bastide A, Touriol C, Prats H, Trombe MC.

J Bacteriol. 2009 Aug;191(15):4943-50. doi: 10.1128/JB.00196-09. Epub 2009 Jun 5.

27.

The VEGF IRESes are differentially susceptible to translation inhibition by miR-16.

Karaa ZS, Iacovoni JS, Bastide A, Lacazette E, Touriol C, Prats H.

RNA. 2009 Feb;15(2):249-54. doi: 10.1261/rna.1301109.

28.

An upstream open reading frame within an IRES controls expression of a specific VEGF-A isoform.

Bastide A, Karaa Z, Bornes S, Hieblot C, Lacazette E, Prats H, Touriol C.

Nucleic Acids Res. 2008 Apr;36(7):2434-45. doi: 10.1093/nar/gkn093. Epub 2008 Feb 26.

29.

Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress.

Bornes S, Prado-Lourenco L, Bastide A, Zanibellato C, Iacovoni JS, Lacazette E, Prats AC, Touriol C, Prats H.

Circ Res. 2007 Feb 16;100(3):305-8. Epub 2007 Jan 25.

PMID:
17255526
30.

Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.

Krejci P, Masri B, Salazar L, Farrington-Rock C, Prats H, Thompson LM, Wilcox WR.

J Biol Chem. 2007 Feb 2;282(5):2929-36. Epub 2006 Dec 4.

31.

Essential role of bone marrow fibroblast growth factor-2 in the effect of estradiol on reendothelialization and endothelial progenitor cell mobilization.

Fontaine V, Filipe C, Werner N, Gourdy P, Billon A, Garmy-Susini B, Brouchet L, Bayard F, Prats H, Doetschman T, Nickenig G, Arnal JF.

Am J Pathol. 2006 Nov;169(5):1855-62.

32.

Testosterone regulates FGF-2 expression during testis maturation by an IRES-dependent translational mechanism.

Gonzalez-Herrera IG, Prado-Lourenco L, Pileur F, Conte C, Morin A, Cabon F, Prats H, Vagner S, Bayard F, Audigier S, Prats AC.

FASEB J. 2006 Mar;20(3):476-8. Epub 2006 Jan 19. Erratum in: FASEB J. 2006 Jul;20(9):1573-4.

PMID:
16423876
33.

Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis.

Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, Wilcox WR.

J Cell Sci. 2005 Nov 1;118(Pt 21):5089-100. Epub 2005 Oct 18.

34.

Antiangiogenic properties of fibstatin, an extracellular FGF-2-binding polypeptide.

Bossard C, Van den Berghe L, Laurell H, Castano C, Cerutti M, Prats AC, Prats H.

Cancer Res. 2004 Oct 15;64(20):7507-12.

35.

Internal ribosome entry site structural motifs conserved among mammalian fibroblast growth factor 1 alternatively spliced mRNAs.

Martineau Y, Le Bec C, Monbrun L, Allo V, Chiu IM, Danos O, Moine H, Prats H, Prats AC.

Mol Cell Biol. 2004 Sep;24(17):7622-35.

36.

Role of fibroblast growth factor-2 isoforms in the effect of estradiol on endothelial cell migration and proliferation.

Garmy-Susini B, Delmas E, Gourdy P, Zhou M, Bossard C, Bugler B, Bayard F, Krust A, Prats AC, Doetschman T, Prats H, Arnal JF.

Circ Res. 2004 May 28;94(10):1301-9. Epub 2004 Apr 8.

PMID:
15073041
37.

Control of the vascular endothelial growth factor internal ribosome entry site (IRES) activity and translation initiation by alternatively spliced coding sequences.

Bornes S, Boulard M, Hieblot C, Zanibellato C, Iacovoni JS, Prats H, Touriol C.

J Biol Chem. 2004 Apr 30;279(18):18717-26. Epub 2004 Feb 5.

38.

Estrogens and atherosclerosis.

Arnal JF, Gourdy P, Elhage R, Garmy-Susini B, Delmas E, Brouchet L, Castano C, Barreira Y, Couloumiers JC, Prats H, Prats AC, Bayard F.

Eur J Endocrinol. 2004 Feb;150(2):113-7. Review.

PMID:
14763907
39.

Generation of protein isoform diversity by alternative initiation of translation at non-AUG codons.

Touriol C, Bornes S, Bonnal S, Audigier S, Prats H, Prats AC, Vagner S.

Biol Cell. 2003 May-Jun;95(3-4):169-78. Review.

PMID:
12867081
40.

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, Carmeliet P.

Nat Genet. 2003 Aug;34(4):383-94.

PMID:
12847526
41.

Translokin is an intracellular mediator of FGF-2 trafficking.

Bossard C, Laurell H, Van den Berghe L, Meunier S, Zanibellato C, Prats H.

Nat Cell Biol. 2003 May;5(5):433-9.

PMID:
12717444
42.

Low-molecular-weight fucoidan promotes therapeutic revascularization in a rat model of critical hindlimb ischemia.

Luyt CE, Meddahi-Pellé A, Ho-Tin-Noe B, Colliec-Jouault S, Guezennec J, Louedec L, Prats H, Jacob MP, Osborne-Pellegrin M, Letourneur D, Michel JB.

J Pharmacol Exp Ther. 2003 Apr;305(1):24-30.

PMID:
12649349
43.

Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis.

Prats AC, Prats H.

Prog Nucleic Acid Res Mol Biol. 2002;72:367-413. Review.

PMID:
12206457
44.

New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation.

Huez I, Bornes S, Bresson D, Créancier L, Prats H.

Mol Endocrinol. 2001 Dec;15(12):2197-210.

PMID:
11731620
45.

p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA.

Galy B, Créancier L, Prado-Lourenço L, Prats AC, Prats H.

Oncogene. 2001 Aug 2;20(34):4613-20.

46.

Tumour suppressor p53 inhibits human fibroblast growth factor 2 expression by a post-transcriptional mechanism.

Galy B, Créancier L, Zanibellato C, Prats AC, Prats H.

Oncogene. 2001 Mar 29;20(14):1669-77.

47.

FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2.

Van den Berghe L, Laurell H, Huez I, Zanibellato C, Prats H, Bugler B.

Mol Endocrinol. 2000 Nov;14(11):1709-24.

PMID:
11075807
48.

IL-6 promoter is modulated by the 24 kDa FGF-2 isoform fused to the hormone binding domain of the oestrogen receptor.

Delrieu I, Chinestra P, Delassus F, Bayard F, Prats H, Faye JC.

Cytokine. 2000 Jul;12(7):1110-4.

PMID:
10880259

Supplemental Content

Support Center